Close Menu

Breaking News

The expansion increases the number of PCR instruments and types of reagents and consumables labs can use to run the Applied Biosystems TaqPath COVID-19 Combo Kit.

The company recently received Medicare coverage for the DetermaRx assay that it brought to market through its acquisition of Razor Genomics late last year.

Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.

The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.

The PCR-based test received EUA for use on the Alinity m platform after receiving authorization in March on the firm's m2000 RealTime System. 

Noridian is also developing a generic policy for donor-derived cfDNA tests that will include several commercially available tests, Natera said.

The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.

The skin cancer diagnostics company said it delivered 42 percent more DecisionDx-Melanoma test results in Q1 2020 than in the previous year's first quarter.

A Broad Institute-led team found that differences by ancestry could affect not only how cancer develops but also treatment approaches.

The firm said its test is one-thousandfold  more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.

Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.

Last week, GenomeWeb's readers were most interested in a study suggesting pangolins may have served as an intermediate host for SARS-CoV-2.

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

The PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in various respiratory specimens including oropharyngeal swabs.

The agency reviewed data showing that HRD-positive patients on the olaparib/bevacizumab combination had median progression-free survival of 37.2 months.

The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.

The federal agency approved the use of the Zymo Research SARS-CoV-2 kit with both upper respiratory and lower respiratory specimens.

A GWAS that incorporated magnetic resonance imaging data for UK Biobank participants led to 45 previously undetected risk loci related to dilated cardiomyopathy.

The grants were awarded as part of Australia's Genomics Health Futures Mission, which was launched in 2018 as part of a broader health research initiative.

News items for the week of May 4, 2020. 

SARS-CoV-2 might have resulted from recombination between pangolin and bat coronaviruses, with pangolins serving as an intermediate host.

The test is validated and authorized for numerous extraction technologies and PCR instruments.

Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.